Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

When you start taking GLP-1s, you’re probably excited about the expected changes to your body. These medications were created to lower blood sugar for diabetes, but many are now popularly used for ...

LAS VEGAS — Off-label use of GLP-1 drugs by people with type 1 diabetes (T1D) did not lead to diabetic ketoacidosis (DKA) or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist ...